Chemogenetics

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Currently research-onlyPotential applications in epilepsy, Parkinson’s, depression, addiction, pain

Mechanism

Chemogenetics uses genetically modified receptors (DREADDs) inserted into specific neurons. When activated by a synthetic ligand, these receptors can either increase (hM3Dq) or decrease (hM4Di) neuronal activity, providing selective control over brain circuits.

Protocol

Preparation

Requires gene delivery via viral vectors (AAV, lentivirus) targeting neuronal populations.

Procedure

Surgical or targeted vector delivery of DREADD gene constructs
Recovery and stable receptor expression
Systemic or local administration of activating ligand (e.g., CNO, clozapine)
Behavioral/clinical monitoring of outcomes

Frequency: Ligand dosing as needed

Duration: Ligand effects last hours; receptor expression can persist months–years

Total Treatment Time: Currently indefinite; in practice depends on experimental protocol

Equipment

Viral vector delivery systems
Surgical equipment for stereotactic injection (animal/human preclinical)
Ligand dosing equipment (oral/IV)

Session Structure

Pre-Session

Baseline behavioral and physiological assessment

Post-Session

Washout and follow-up testing

Expected Outcomes

Immediate

Precise modulation of targeted circuits

Short Term

Altered behaviors, improved disease models

Long Term

Potential disease modification if translated safely to humans

Side Effects

common

None inherent, ligand generally inert

uncommon

Off-target drug effects

rare

Immune response to viral vector
Unexpected gene expression effects

Contraindications

absolute

Currently not available as a clinical therapy

relative

Risk of immune response to viral vector

Patient Selection

ideal candidates

Currently limited to animal research

screening required

Future: gene therapy risk assessment

Training Requirements

practitioner

Neuroscientist
Neuroengineer
Potential future: neurosurgeon, gene therapy specialist

facility

Research laboratory with BSL-2/3 capabilities

Research Evidence

Key Studies

Armbruster et al., 2007 – foundational DREADD development.
Roth, 2016 – review of chemogenetics in neuroscience.
Recent translational work in epilepsy and addiction models.

Limitations

Not yet clinically approved; significant barriers to safe human translation.

Cost Considerations

typical session cost: Research dependent

total treatment cost: High (gene therapy + experimental monitoring)

insurance coverage: None

cost effectiveness: Not applicable at clinical level

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

Optogenetics (research)
Neuropharmacology

Special Populations

👶Pregnancy

Not studied

Clinical Notes

Powerful tool for dissecting brain circuitry.
Potential future therapy but major hurdles remain.
Safer ligand design and gene delivery systems are active research areas.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists